These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 9010012)

  • 1. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huntington's disease progression. PET and clinical observations.
    Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
    Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
    Antonini A; Leenders KL; Vontobel P; Maguire RP; Missimer J; Psylla M; Günther I
    Brain; 1997 Dec; 120 ( Pt 12)():2187-95. PubMed ID: 9448574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
    Antonini A; Leenders KL; Eidelberg D
    Ann Neurol; 1998 Feb; 43(2):253-5. PubMed ID: 9485067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.
    Turjanski N; Weeks R; Dolan R; Harding AE; Brooks DJ
    Brain; 1995 Jun; 118 ( Pt 3)():689-96. PubMed ID: 7600086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.
    Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; Dunnett SB; Piccini P
    Brain; 2003 May; 126(Pt 5):1127-35. PubMed ID: 12690052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
    Weeks RA; Piccini P; Harding AE; Brooks DJ
    Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography.
    Künig G; Leenders KL; Sanchez-Pernaute R; Antonini A; Vontobel P; Verhagen A; Günther I
    Ann Neurol; 2000 May; 47(5):644-8. PubMed ID: 10805336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.
    Mazziotta JC; Phelps ME; Pahl JJ; Huang SC; Baxter LR; Riege WH; Hoffman JM; Kuhl DE; Lanto AB; Wapenski JA
    N Engl J Med; 1987 Feb; 316(7):357-62. PubMed ID: 2949152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
    Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
    J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
    Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
    Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride.
    Antonini A; Leenders KL
    Ann N Y Acad Sci; 1993 Sep; 695():81-5. PubMed ID: 8239318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease.
    Kuhl DE; Markham CH; Metter EJ; Riege WH; Phelps ME; Mazziotta JC
    Res Publ Assoc Res Nerv Ment Dis; 1985; 63():199-209. PubMed ID: 3161165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease.
    Kuhl DE; Metter EJ; Riege WH; Markham CH
    Ann Neurol; 1984; 15 Suppl():S119-25. PubMed ID: 6234856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalamic metabolism and symptom onset in preclinical Huntington's disease.
    Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D
    Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothalamic involvement in Huntington's disease: an in vivo PET study.
    Politis M; Pavese N; Tai YF; Tabrizi SJ; Barker RA; Piccini P
    Brain; 2008 Nov; 131(Pt 11):2860-9. PubMed ID: 18829696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal caudate glucose metabolism in persons at risk for Huntington's disease.
    Young AB; Penney JB; Starosta-Rubinstein S; Markel D; Berent S; Rothley J; Betley A; Hichwa R
    Arch Neurol; 1987 Mar; 44(3):254-7. PubMed ID: 2950844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.